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Abstract
Introduction: Bile acids (BAs) are the end products of cholesterol metabolism produced by 
human and gut microbiome co-metabolism. Recent evidence suggests gut microbiota influence 
pathological features of Alzheimer’s disease (AD) including neuroinflammation and amyloid-β 
deposition.
Method: Serum levels of 20 primary and secondary BA metabolites from the AD Neuroimaging 
Initiative (n=1562) were measured using targeted metabolomic profiling. We assessed the 
association of BAs with the “A/T/N” (Amyloid, Tau and Neurodegeneration) biomarkers for AD: 
CSF biomarkers, atrophy (MRI), and brain glucose metabolism ([18F]FDG-PET).
Results: Of 23 BA and relevant calculated ratios after quality control procedures, three BA 
signatures were associated with CSF Aβ1–42 (“A”) and three with CSF p-tau181 (“T”) (corrected 
p<0.05). Furthermore, three, twelve, and fourteen BA signatures were associated with CSF t-tau, 
glucose metabolism, and atrophy (“N”), respectively (corrected p<0.05).
Conclusion: This is the first study to show serum-based BA metabolites are associated with 
“A/T/N” AD biomarkers, providing further support for a role of BA pathways in AD 
pathophysiology. Prospective clinical observations and validation in model systems are needed to 
assess causality and specific mechanisms underlying this association.
Keywords
Metabolomics; bile acid; Alzheimer’s disease; amyloid-β; CSF biomarkers; brain glucose 
metabolism; PET; MRI; gut liver brain axis
1. Introduction
Several metabolic perturbations have been noted in Alzheimer’s disease (AD) including 
failures associated with cholesterol metabolism [1–3], which has been associated with AD in 
multiple lines of research including physiological and epidemiological studies [3–5]. Bile 
acids (BAs) are synthesized from cholesterol and are involved in the digestion of lipids and 
absorption of fat soluble vitamins[6]. Cholesterol is synthesized in liver and its clearance 
involves bile acid (BA) production by gut microbiome and human co-metabolism. Changes 
in microbial gut populations can profoundly alter BA profiles and signaling [7–9]. BA 
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synthesis can also be regulated by fat soluble vitamins through repression of the rate-
limiting enzyme Cytochrome P450 7A (CYP7A1) [6]. Activation of the Vitamin D Receptor 
(VDR) is the mechanism by which vitamin D affects BA homeostasis whereas the action of 
vitamin A is mediated through the Retinal X Receptor/Farnesoid X Receptor (RXR/FXR) 
heterodimer [6]. Vitamin-D dependent regulation of BA synthesis may be an additional 
mechanism by BA influence AD pathophysiology as vitamin D has been shown to be 
protective against risk of AD and cognitive impairments [10, 11].
Bile acids appear to play a role in the central nervous system [12, 13]. Recent work suggests 
microbial disturbances linked to BA profiles are implicated in neurodegenerative disorders 
[7–9, 14–16]. The gut microbiota are involved in immune, neuroendocrine, and neural 
pathways[8, 9, 17–21], have been shown to regulate microglial maturation and function, and 
may contribute to AD [21, 22].
Peripheral metabolic changes may influence central changes through the liver and gut-brain 
axis that includes commensal and pathogenic bacteria, through its interactions with the 
vagus nerve, changes in central nervous system functioning, the immune system[23, 24], and 
hippocampal neurogenesis [25]. These signals are crucial for the regulation of energy, 
glucose homeostasis and inflammation [26]. Gut microbiota are vital to the transformation 
of bile acid through their deconjugation, dihydroxylation, and reconjugation [16]. The gut-
brain biochemical axis of communication is just starting to be elucidated. Circulating BAs 
seem to provide an important mechanism for communication between the gut and the brain, 
and their alterations reflect gut dysbiosis [8, 9, 18]. Previous studies suggest that BAs are 
altered in mild cognitive impairment (MCI) and AD [27], and in the preceding paper, we 
showed that increased levels of secondary cytotoxic BAs and their ratios to primary BAs 
were associated with AD and poor cognition. This supported the hypothesis that circulating 
BAs may contribute to AD pathogenesis. Research in AD animal models suggests a role for 
the gut microbiome in the development of amyloid-β pathology[28].
However, little work has been done in humans to link peripheral metabolic changes in 
cholesterol to central biomarkers related to AD including amyloid-β and tau accumulation, 
brain glucose metabolism, and structural atrophy. Therefore, we analyzed serum BA 
metabolites and their ratios from older adults with early stage AD or who were at risk for 
AD from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort.
We hypothesized that serum BA levels and their relevant ratios would associate with 
biomarkers of AD pathophysiology including neuroimaging (MRI and PET) and 
cerebrospinal fluid (CSF). The AD biomarkers were selected and defined consistent with the 
recent NIA-Alzheimer’s Association Research Framework (“A/T/N”) for AD biomarkers 
that defines three general groups of biomarkers based on the nature of pathologic process 
that each measures [29–31]. This approach has several strengths including the focus on 
biological underpinnings of the disease rather than clinical phenotypes which may have 
different pathophysiological substrates as well as making no assumptions based on the 
temporal order of the biomarkers included or their potential causal relationships. Biomarkers 
of amyloid-β plaque (“A”) are CSF Aβ1–42 and cortical amyloid-β accumulation measured 
by Florbetapir PET, biomarkers of fibrillary tau (“T”) are CSF phosphorylated tau (p-tau), 
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and biomarkers of neurodegeneration or neuronal injury (“N”) are atrophy on MRI, glucose 
metabolism on FDG PET, and CSF total tau (t-tau).
2. Methods
2.1. Study cohort
Serum samples and data analyzed in the present report were obtained from ADNI. The 
initial phase (ADNI-1) was launched in 2003 to test whether serial magnetic resonance 
imaging (MRI), position emission tomography (PET), other biological markers, and clinical 
and neuropsychological assessment could be combined to measure the progression of MCI 
and early AD. ADNI-1 was extended to subsequent phases (ADNI-GO, ADNI-2, and 
ADNI-3) for follow-up for existing participants and additional new enrollments. Inclusion 
and exclusion criteria, clinical and neuroimaging protocols, and other information about 
ADNI can be found at www.adni-info.org [32, 33]. Demographic information, raw 
neuroimaging scan data, APOE, neuropsychological test scores, and clinical information are 
available and were downloaded from the ADNI data repository (www.loni.usc.edu/ADNI/). 
Written informed consent was obtained at the time of enrollment that included permission 
for analysis and data sharing and consent forms were approved by each participating sites’ 
Institutional Review Board (IRB).
2.2. Quality control procedures of serum bile acid profiles
Targeted metabolomics profiling was performed to identify and quantify concentrations of 
20 BAs from serum samples using Biocrates® Bile Acids Kit as described in detail in the 
companion paper in this volume (MahmoudianDehkordi et al, 2018 submitted). In brief, 
morning serum samples from the baseline visit were collected and aliquoted as described in 
the ADNI standard operating procedures, with only fasting samples included in this study 
[32]. BA quantification was performed by liquid chromatography tandem mass 
spectrometry. Metabolites with >40% of measurements below the lower limit of detection 
(<LOD) were excluded. To assess the precision of the measured analytes, a set of blinded 
analytical replicates (24 pairs in ADNI-1 and 15 triples in ADNI-GO/2) were supplied by 
ADNI. Unblinded metabolite profiles went through further quality control (QC) checks. 
Validation of the kit was completed with acceptable inter- and intra-laboratory 
reproducibility as part of an international ring trial on the Bile Acids Kit from Biocrates AG, 
published in 2016 [34]. Inter-plate variability was monitored using a series of quality control 
samples, including low, mid, and high QC that come with the kit, a study pool QC analyzed 
in triplicate on each plate, and the NIST SRM-1950 reference material in duplicate on each 
plate, and only analytes with <30% technical reproducibility were included in subsequent 
analysis. The coefficient of variation (range 6.25, 21.49) and intra-class correlation 
coefficients (range 0.89, 0.99) are presented in Supplementary Table 1. The preprocessed 
dataset included 15 BAs (5 BAs did not pass QC criteria) and 8 ratios. These selected ratios 
reflect enzymatic dysfunctions in liver and changes in gut microbiome metabolism (see Fig 
1b and Section 2.3). The preprocessed BA values obtained from the QC step were adjusted 
for the effect of medication use (at baseline) on BA levels (see Toledo et al. 2017 [35] for 
adjustment description details).
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2.3. Ratios reflective of conversion of BAs by gut microbiome
We investigated eight selected ratios that are thought to be reflective of enzymatic activities 
in the liver and the gut microbiome to determine in these enzymatic processes in BA 
metabolism are associated with neuroimaging and CSF biomarkers of AD. These ratios 
include:
1. CA:CDCA ratio was selected to test if a possible shift in BA synthesis from the 
primary to the alternative BA pathways occurs in the liver.
2. Ratios of secondary to primary BAs (DCA:CA, GLCA:CDCA, and 
TLCA:CDCA) to examine differences in the gut microbiome enzymatic activity 
leading to altered production of secondary of secondary BAs. Because LCA was 
excluded in QC steps, the GLCA:CDCA and TLCA:CDCA ratios were used as 
proxies for LCA:CDCA ratio.
3. GDCA:DCA and TDCA:DCA ratios were used to test if the observed secondary 
BA dysregulation is related to enzymatic differences related to conjugation.
2.4. Neuroimaging processing
2.4.1. Magnetic Resonance Imaging (MRI)—T1-weighted brain MRI scans at 
baseline were acquired using a sagittal 3D MP-RAGE sequence following the ADNI MRI 
protocol [36, 37]. As detailed in previous studies, FreeSurfer V5.1, a widely employed 
automated MRI analysis approach, was used to process MRI scans and extract whole brain 
and ROI (region of interest)-based neuroimaging endophenotypes including volumes and 
cortical thickness determined by automated segmentation and parcellation [38–40]. The 
cortical surface was reconstructed to measure thickness at each vertex. The cortical thickness 
was calculated by taking the Euclidean distance between the grey/white boundary and the 
grey/cerebrospinal fluid (CSF) boundary at each vertex on the surface [41–43].
2.4.2. Positron Emission Tomography (PET)—Pre-processed [18F] FDG and [18F] 
Florbetapir PET scans (co-registered, averaged, standardized image and voxel size, uniform 
resolution) were downloaded from the ADNI LONI site (http://adni.loni.usc.edu) as 
described in previously reported methods for acquisition and processing of PET scans from 
the ADNI sample.[38, 44] For [18F] FDG PET, scans were intensity-normalized using a 
pons ROI to create [18F] FDG standardized uptake value ratio (SUVR) images. For [18F] 
Florbetapir PET, scans were intensity-normalized using a whole cerebellum reference region 
to create SUVR images.
2.5. CSF Aβ1–42, t-tau, and p-tau181 biomarkers
ADNI generated CSF biomarkers (Aβ1–42, t-tau and p-tau181) in pristine aliquots of 2,401 
ADNI CSF samples using the validated and highly automated Roche Elecsys® 
electrochemiluminescence immunoassays [45, 46] and the same reagent lot for each of these 
three biomarkers. The CSF biomarker data was downloaded from the ADNI LONI site 
(http://adni.loni.usc.edu).
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2.6. Statistical analyses
2.6.1. CSF biomarkers—We performed a linear regression analysis using age, sex, 
study phase (ADNI-1 or ADNI-GO/2), body mass index (BMI), and APOE ε4 status as 
covariates, followed by false discovery rate (FDR)-based multiple comparison adjustment 
with the Benjamini-Hochberg procedure.
2.6.2. Region of Interest (ROI) based analysis of structural MRI and PET—
Mean hippocampal volume was used as an MRI-related phenotype. For FDG PET, a mean 
SUVR value was extracted from a global cortical ROI representing regions where AD 
patients show decreased glucose metabolism relative to cognitively normal older participants 
(CN) from the full ADNI-1 cohort, normalized to pons.[44] For [18F] Florbetapir PET, a 
mean SUVR value was extracted using MarsBaR from a global cortical region generated 
from an independent comparison of ADNI-1 [11C]Pittsburgh Compound B SUVR scans 
(regions where AD > CN). We performed a linear regression analysis using age, sex, BMI, 
study phase (ADNI-1 or ADNI-GO/2), and APOE ε4 status as covariates. For hippocampal 
volume, years of education, intracranial volume (ICV), and magnetic field strength were 
added as additional covariates. FDR-based multiple comparison adjustment with the 
Benjamini-Hochberg procedure was used because the AD biomarker phenotypes were 
strongly correlated with each other.[47] Not accounting for this high collinearity of 
dependent variables would lead to an overly stringent correction for multiple testing.
2.6.3. Whole brain imaging analysis—The SurfStat software package 
(www.math.mcgill.ca/keith/surfstat/) was used to perform a multivariate analysis of cortical 
thickness to examine the effect of BA profiles on brain structural changes on a vertex-by-
vertex basis using a general linear model (GLM) approach.[43] GLMs were developed using 
age, sex, years of education, ICV, BMI, APOE ε4 status, and magnetic field strength as 
covariates. The processed FDG PET images were used to perform a voxel-wise statistical 
analysis of the effect of BA levels on brain glucose metabolism across the whole brain using 
SPM8 (www.fil.ion.ucl.ac.uk/spm/). We performed a multivariate regression analysis using 
age, sex, BMI, APOE ε4 status, and study phase (ADNI-1 or ADNI-GO/2) as covariates. In 
the whole brain surface-based analysis, the adjustment for multiple comparisons was 
performed using the random field theory correction method with p<0.05 adjusted as the level 
for significance.[48–50]. In the voxel wise whole brain analysis, the significant statistical 
parameters were selected to correspond to a threshold of p < 0.05 (FDR-corrected).
3. Results
3.1. Study sample after QC
After QC procedures, 1,562 ADNI participants with 23 BAs and their relevant ratio levels 
(15 BA metabolites and 8 ratios) at baseline (370 cognitively normal older adults (CN), 98 
significant memory concern (SMC), 284 early MCI (EMCI), 505 late MCI (LMCI), and 305 
AD) were available for analysis. Demographic information for the study population is 
presented in Table 1. Mean and standard errors of primary and secondary BAs stratified by 
clinical diagnosis are presented in Supplementary Table 2.
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3.2. Biomarkers of amyloid-β (“A”)
We used CSF Aβ1–42 levels and a global cortical amyloid deposition of amyloid PET as 
biomarkers of amyloid-β. First, we evaluated whether BA profiles were associated with CSF 
Aβ1–42 biomarker by performing an association analysis for 15 BA metabolites and 8 
relevant ratios with APOE ε4 status as a covariate. As shown in Fig 1a, after applying FDR-
based multiple comparison correction, we identified three BA ratios significantly associated 
with CSF Aβ1–42 levels. Regression coefficients of the three BA ratios of bacterially 
produced conjugated secondary BAs to primary BAs (GDCA:CA, TDCA:CA, and 
GLCA:CDCA) showed negative associations indicating higher levels were associated with 
lower CSF Aβ1–42 values (CSF Aβ142 positivity). However, global cortical amyloid 
deposition of amyloid PET was not significantly associated with any BA or their ratios after 
applying FDR-based multiple comparison correction. GDCA:CA was marginally associated 
with a global cortical amyloid load (uncorrected p-value < 0.05). Higher GDCA:CA levels 
were associated with greater amyloid deposition.
3.3. Biomarkers of fibrillary tau (“T”)
We used CSF phosphorylated tau (p-tau) levels as the biomarker of fibrillary tau. We 
investigated the association of 23 BAs and their relevant ratios with CSF p-tau, with APOE 
ε4 status included as a covariate. We identified three significant associations (FDR-corrected 
p<0.05) (Fig 1a). For one conjugated primary BA metabolite (GCDCA), higher GCDCA 
levels were associated with higher CSF p-tau values. For two bacterially produced 
conjugated secondary BA metabolites (GLCA and TLCA), higher levels were correlated 
with higher CSF p-tau values.
3.4. Biomarkers of neurodegeneration or neuronal injury (“N”)
We used atrophy on T1-weighted MRI, hypometabolism on FDG PET, and CSF total tau (t-
tau) levels as biomarkers of neurodegeneration or neuronal injury.
3.4.1. Structural MRI (atrophy)—We investigated the association of BA metabolites 
and ratios with mean hippocampal volume with APOE ε4 status as a covariate. Among 23 
BA characteristics, 14 BAs/ratios were significantly associated with hippocampal volume 
after controlling for multiple testing using FDR (Fig 1a; corrected p<0.05). For one primary 
BA metabolite, lower CA levels were associated with decreased hippocampal volume. 
However, for two conjugated primary BA metabolites (GCDCA and TMCA(a+b)) and five 
bacterially produced conjugated secondary BA metabolites (GDCA, GLCA, GUDCA, 
TDCA, and TLCA), higher BA levels were associated with decreased hippocampal volume. 
In addition, higher levels of six ratios of bacterially produced secondary BA metabolite to 
primary BA metabolite (DCA:CA, GDCA:CA, TDCA:CA, GDCA:DCA, GLCA:CDCA, 
and TLCA:CDCA) were associated with decreased hippocampal volume.
Among the 14 significant BA signatures, six BA profiles were significantly associated with 
CSF Aβ1–42 biomarker (“A”) or CSF p-tau biomarker (“T”). For the six BA profiles, we 
performed a detailed whole-brain surface-based analysis using multivariate regression 
models and assessed their effects on whole-brain cortical thickness in an unbiased way. We 
identified significant associations for all six BA profiles (cluster wise threshold of RFT-
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corrected p < 0.05), which showed consistent patterns in the associations of CSF Aβ1–42 or 
p-tau levels (Fig 2). Higher levels of a conjugated primary BA (GCDCA) were significantly 
associated with reduced cortical thickness especially in bilateral entorhinal cortices. 
Increased levels of one bacterially produced conjugated secondary BA metabolite (GLCA) 
and two ratios of bacterially produced secondary BA metabolites to primary BA metabolites 
(GDCA:CA and GLCA:CDCA) were significantly associated with reduced cortical 
thickness in the bilateral frontal, parietal, and temporal lobes including the entorhinal cortex. 
For one bacterially produced conjugated secondary BA metabolite (TLCA) and one ratio of 
a bacterially produced secondary BA metabolite to a primary BA metabolite (TDCA:CA), 
increased levels were associated with reduced cortical thickness in a widespread pattern, 
especially in the bilateral frontal, parietal, and temporal lobes.
3.4.2. FDG-PET (brain glucose metabolism)—We performed an association 
analysis for 23 BA and ratios with global cortical glucose metabolism measured by FDG 
PET scans across 1,066 participants with both FDG PET scans and BA measurements. The 
association testing including APOE ε4 status as a covariate, identified twelve BA 
characteristics as significantly associated with brain glucose metabolism after controlling for 
multiple testing using FDR (Fig 1a; corrected p<0.05). For one primary BA metabolite, 
lower CA levels were associated with reduced glucose metabolism. In contrast, for one 
conjugated primary BA metabolite (GCDCA), four bacterially produced conjugated 
secondary BA metabolites (GDCA, GLCA, TDCA, and TLCA), and six ratios of bacterially 
produced secondary BA metabolites to primary BA metabolites (DCA:CA, GDCA:CA, 
TDCA:CA, GDCA:DCA, GLCA:CDCA, and TLCA:CDCA), higher BA ratio levels were 
associated with reduced glucose metabolism.
In addition, in an unbiased way we performed a detailed whole-brain analysis to determine 
the effect of BAs on brain glucose metabolism on a voxel wise level for six BAs and ratios 
(GCDCA, GLCA, TLCA, GDCA:CA, TDCA:CA, and GLCA:CDCA) that were 
significantly associated with both CSF Aβ1–42 or p-tau biomarkers, FDG metabolism, and 
hippocampal volume. We identified significant associations for all six BA profiles (cluster 
wise threshold of FDR-corrected p < 0.05), which showed consistent patterns in the 
associations of CSF Aβ1–42 or p-tau levels and structural atrophy (Fig 3). Higher levels of a 
conjugated primary bile acid GCDCA were significantly associated with reduced glucose 
metabolism especially in the bilateral hippocampi, which showed consistent patterns with 
the associations of cortical thickness. Increased levels of one bacterially produced 
conjugated secondary BA metabolite (GLCA) and one ratio of a bacterially produced 
secondary BA metabolite to a primary BA metabolite (GLCA:CDCA) were significantly 
associated with reduced glucose metabolism in the bilateral temporal and parietal lobes. 
Lower TLCA levels, a bacterially produced conjugated secondary BA metabolite, were 
associated with increased glucose metabolism in the left temporal lobe. For two ratios 
(GDCA:CA and TDCA:CA) of bacterially produced secondary BA metabolite to a primary 
BA metabolite, higher ratio levels were significantly associated with reduced glucose 
metabolism in a widespread pattern, especially in the bilateral frontal, parietal, and temporal 
lobes.
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3.4.3. CSF total tau (t-tau)—We evaluated whether 23 BAs and ratios were associated 
with the CSF t-tau including APOE ε4 status as a covariate. We identified three significant 
associations after controlling for multiple testing using FDR (corrected p<0.05) (Fig. 1). 
Higher levels of GCDCA, a conjugated primary BA metabolite, and GLCA and TLCA, 
bacterially produced secondary BA metabolites, were associated with higher CSF t-tau 
values.
4. Discussion
In this report we analyzed serum-based BA profiles in the ADNI cohort to investigate the 
relationship between peripheral metabolic measures and central biomarkers for AD 
pathophysiology based on the recently proposed framework (“A/T/N”).[30] Our results 
showed that altered BA profiles were significantly associated with structural and functional 
changes in the brain as noted by larger atrophy and reduced glucose metabolism (“N”). 
Furthermore, altered BA profiles were significantly associated with three CSF biomarkers 
including Aβ1–42, t-tau, and p-tau. Three ratios of primary BAs to secondary BAs were 
associated with lower CSF Aβ1–42 levels (amyloid-β positivity) (“A”) as well as reduced 
cortical glucose metabolism and larger structural atrophy (GDCA:CA, TDCA:CA, and 
GLCA:CDCA). One conjugated primary BA profile (GCDCA) and two bacterially produced 
conjugated secondary BAs (GLCA and TLCA) were associated with higher CSF p-tau 
values (“T”) as well as higher CSF t-tau values, reduced glucose metabolism, and larger 
structural atrophy.
Whether the gut microbiome directly influences AD pathogenesis remains unknown, 
however it does appear to influence amyloid-β, fibrillary tau, and neurodegeneration. To our 
knowledge, this is the first study to systematically link markers of the gut microbiome and 
liver function to AD-related structural and functional neuroimaging biomarkers as well as 
biomarkers of amyloid-β and tau burden.
Three core CSF biomarkers (Aβ1–42, t-tau, and p-tau) reflect AD pathology and can be 
used to reliably diagnose AD and identify MCI, a prodromal stage of AD, with high 
diagnostic accuracy.[51, 52] Previous studies showed that AD patients have a substantial 
reduction in CSF Aβ1–42 and a marked increase in levels of CSF t-tau and p-tau [53–56]. 
We observed that higher levels of TDCA:CA, GDCA:CA, and GLCA:CDCA were 
associated with decreased levels of CSF Aβ1–42 and higher levels of GCDCA, TLCA, and 
GLCA were associated with increased levels of CSF t-tau and p-tau.
MRI is widely used to investigate structural changes in MCI and AD.[57–59] We observed 
lower levels of CA and higher levels of GCDCA, TMCA(a+b), GDCA, GLCA, GUDCA, 
TDCA, TLCA, DCA:CA, GDCA:CA, TDCA:CA, GDCA:DCA, GLCA:CDCA, and 
GCDCA:CDCA were associated with greater brain atrophy. Significant regional effects were 
observed particularly in the bilateral inferior parietal gyri cortices, hippocampi, and temporal 
lobes including the entorhinal cortex. The hippocampus and entorhinal cortex are affected 
early in AD, and the decrease in hippocampal volume accelerates as AD progresses. 
Significant thinning of the cortical surface reflects atrophy in the temporal, parietal, and 
frontal lobes has been shown in MCI and AD.[57–59] Reduced cortical thickness in the 
Nho et al. Page 9
Alzheimers Dement. Author manuscript; available in PMC 2019 April 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
temporal cortex as a measure of brain atrophy rate has shown promise in predicting MCI to 
AD progression.[57]
Lower CA and higher TDCA, GDCA, GCDCA, GLCA, TLCA, DCA:CA, GDCA:CA, 
TDCA:CA, GDCA:DCA, GLCA:CDCA, and TLCA:CDCA levels were associated with 
reduced global glucose metabolism in brain. The significant regional effect on brain glucose 
metabolism was observed particularly in the bilateral hippocampi for GCDCA, in the 
temporal and parietal lobes for GLCA, TLCA, and GLCA/CDCA, and in a widespread 
pattern including the bilateral temporal, parietal, and frontal lobes for GDCA:CA and 
TDCA:CA. AD patients have shown significant glucose metabolism reduction in the 
temporal lobes, parietal lobes, and then the frontal lobes with increasing severity of AD [60–
62].
The observed pattern of association between changes in brain structure and glucose 
metabolism as well as CSF biomarkers with specific BAs and ratios indicates a potential 
mechanistic connection between peripheral and central biochemical changes. Our results 
strongly suggest gut-liver-brain axis involvement in AD, neurodegeneration, and brain 
dysfunction. Both liver function and gut microbiome activity are impacted in AD, and these 
changes seem to occur at the earliest stages of disease. Despite this strong pattern of 
associations, the specific mechanism and causal directionality remains to be determined.
We hypothesized that altered gut microbiota play an important role. This is supported by 
several lines of research connecting the gut microbiota and AD pathology. Alterations in the 
gut microbiota and an increase in gut permeability may lead to dysfunction in the 
hippocampus [63, 64] and the development of insulin resistance, which correlates with AD 
pathogenesis.[65–67] It has been hypothesized that increased gut permeability allows 
bacteria-derived amyloids from the gastrointestinal tract to accumulate at the systemic and 
brain level [68]. This in turn could lead to the upregulation of pro-inflammatory 
microRNA-34a and as a consequence, downregulation of TREM2 leading to the 
accumulation of Aβ42.[67, 68]
Results from animal studies demonstrate that increased input of BAs significantly inhibits 
two of the major phyla in the human gut microbiome, Bacteroidetes and Actinobacteria.[69] 
Bacterial taxonomic composition of fecal samples revealed differences in bacterial 
abundance including decreased Firicutes, increased Bacteroidetes, and decreased 
Bifidobacterium (phylum Actinobaceria) in the microbiome of AD patients relative to age- 
and sex- matched controls. Furthermore, these differences in bacterial abundance correlated 
with CSF biomarkers including Aβ42/Aβ40 and p-tau/Aβ42. Even in the age- and sex-
matched controls (no dementia diagnosis), there was a similar relationship between the same 
bacteria that were either more or less abundant in AD and markers of tau and amyloid.[70] 
In another study, an increased abundance of pro-inflammatory bacteria (Escherichia/
Shigella) and a decreased abundance of anti-inflammatory bacteria (Eubacterium rectale) 
were noted in cognitively impaired older adults with evidence of amyloid deposition on PET 
imaging compared to those who were amyloid negative.[71] These results lend further 
support to the link between gut microbiota and brain amyloidosis. Gut microbiota have been 
associated with the accumulation of amyloid plaques in a mouse model of AD. A transgenic 
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AD mouse model generated under germ-free conditions had dramatic reductions in cerebral 
amyloid-β pathology compared to control animals with normal intestinal microbiota 
whereas, colonization of germ-free AD mice with microbiota harvested from conventionally 
raised AD mice significantly increased Aβ pathology.[28]
The association between BA cytotoxicity and the generation of reactive oxygen species 
(ROS) is well documented [72–76]. Others have proposed that mitochondrial ROS 
production plays an important role in brain metabolic signaling [77, 78]. Some of the 
mechanisms by which mitochondrial dysfunction leads to neuronal degeneration in AD 
include ROS generation and activation of mitochondrial permeability transition [79, 80], 
suggesting a crucial role for oxidative stress in the pathophysiology of AD. 
Hyperphosphorylation of tau proteins has been linked to oxidation through the microtubule-
associated protein kinase pathway [81]. In our analyses, three cytotoxic BAs (GCDCA, 
GLCA, and TLCA) correlated with higher biomarker levels of fibrillary tau and 
neurodegeneration/neuronal injury.
Hydrophobic BAs, like CDCA, are known to damage biological membranes [82], whereas 
hydrophilic BAs, like UDCA and TUDC, are inhibitors of apoptosis via their ability to 
stabilize mitochondrial membranes.[83, 84] Impairment of mitochondrial function is likely 
one of the vital ways in which BAs cause cellular dysfunctions [85–88]. Decreased 
mitochondrial membrane potential has been associated with increasing concentrations of the 
bile acids, LCA, DCA, UDCA, CDCA, GCDC, and taurochenodeoxcholic (TCDC) acid 
[85].
4.1. Limitations
The ADNI study is observational by design making it difficult to control for confounding as 
well as to determine directionality of associations and causal pathways. For example, the 
population of the gut is affected by a plethora of factors including geography, lifetime 
immunological experience, and environmental factors, which could play important, yet 
currently unknown roles in the pathogenesis of AD. Experimental studies are needed to 
understand the mechanistic role of BA in the development of AD-related pathology as well 
as to disentangle cause and effect. Medication use was extensively explored as a potential 
confounder (Supplementary Fig. 2). Overall, our key findings remained significant after 
adjustment for medication use, although effects were attenuated. In addition, further studies 
are warranted to validate our findings in independent cohorts. In this paper, we focus on 
secondary BAs that are only known to be synthesized by bacterial enzymes. It is possible 
that there might be an alternative route to their synthesis that is yet to be discovered. These 
additional regulatory mechanisms could be responsible for the observed changes.
Currently, no large-scale clinical studies (like ADNI) have collected fecal materials to 
interrogate changes in the gut microbiome composition. Future studies we are planning in 
coordination with large AD centers will enable collection of matching blood and fecal 
materials where the composition of the gut microbiome across the trajectory of disease can 
be investigated. There is an urgent need to elucidate mechanistic links between gut microbial 
metabolism and brain function in AD. Existing studies elucidating relations between gut 
microbial metabolism and the human metabolome have mainly used statistical analyses to 
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correlate individual compounds with microbial taxa [89, 90]. However, correlation does not 
necessarily equal causation as the microbiome may change due to AD-related metabolic 
pathology including weight loss. Longitudinal studies that capture both the metagenome and 
metabolome along with fecal samples and dietary information are needed to begin to clarify 
the relationship between bile acid metabolism, gut dysbiosis, and AD.
5. Conclusions
This is the first study to our knowledge to demonstrate an association between altered BA 
profiles and amyloid-β, tau, and neurodegeneration biomarkers of AD pathophysiology. 
While our results provide further evidence implicating BA signaling in AD, the causal 
pathway remains to be systematically investigated by prospective clinical studies and 
experimental manipulations in model systems. Future metagenomics studies are also needed 
to define the relationship between BAs, host factors including genetics, and bacterial 
community composition within an individual across time. Building on present results, these 
investigations are needed to achieve a mechanistic understanding of the role of gut bacteria 
and BAs in relation to AD pathophysiology. If a causal role can be demonstrated in future 
research, BA signaling pathways may lead to the identification of metabolites that are 
protective against AD and could foster novel therapeutic strategies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Research in Context
1. Systematic review: The authors reviewed the literature using PubMed, 
Google, Web of Science, and through meeting abstracts and presentations. We 
have cited several recent publications implicating the gut microbiome role in 
neuropsychiatric diseases.
2. Interpretation: This is the first study to show that serum bile acid (BA) 
produced in liver and by gut microbiome are associated with CSF biomarkers 
and brain imaging changes in AD. BAs play key role in cholesterol clearance 
and in maintaining energy homeostasis. Inter-organ communication seems 
important in maintaining brain glucose metabolism the dysregulation of 
which contributes to neurodegeneration in AD.
3. Future directions: Understanding gut microbiome’s role in aging and related 
diseases opens potential new hypotheses for AD. Prospective clinical 
observations and validation in model systems are needed to assess causality 
and specific mechanisms underlying BA and gut microbiome dysbiosis in 
AD. Biochemical gut-liver-brain axis of communication should be further 
evaluated in AD.
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Fig 1. Bile acids and their ratios reflective of gut microbiome and liver enzymatic activities and 
their correlation with ATN biomarkers for Alzheimer’s disease.
Heat map of q-values of association between bile acid profiles and the “A/T/N” biomarkers 
for AD (a). P-values estimated from linear regression analyses were corrected for multiple 
testing using FDR (q-value). Color code: white indicates q-value>0.05, reds indicate 
significant positive associations, and greens indicate significant negative associations. 
Several ratios were calculated to inform about possible enzymatic activity changes in AD 
(b). These ratios reflect: (1) Shift in bile acid metabolism from primary to alternative 
pathway, (2) Changes in gut microbiome correlated with production of secondary bile acids, 
and (3) Changes in glycine and taurine conjugation of secondary bile acids. LCA was 
excluded in prepossessing checks.
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Fig 2. Whole-brain surface-based imaging analysis
A whole-brain multivariate analysis of cortical thickness across the brain surface was 
performed to visualize the topography of the association of bile acid profiles with brain 
structure in an unbiased manner. For a surface-based analysis of levels of CDCA, TLCA, 
GLCA, TDCA:CA, GDCA:CA, and GLCA:CDCA, statistical maps were thresholded using 
a random field theory for a multiple testing adjustment to a corrected significance level of 
0.05. The p-value for clusters indicates significant corrected p values with the lightest blue 
color. Higher GCDCA levels were significantly associated with reduced cortical thickness 
especially in bilateral entorhinal cortices. Increased GLCA, GDCA:CA, and GLCA:CDCA 
levels were significantly associated with reduced cortical thickness in the bilateral frontal, 
parietal, and temporal lobes including the entorhinal cortex. For TLCA and TDCA:CA, 
increased levels were associated with reduced cortical thickness in a widespread pattern, 
especially in the bilateral frontal, parietal, and temporal lobes.
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Fig 3. Whole-brain voxel-based imaging analysis
A whole-brain multivariate analysis of glucose metabolism was performed to visualize the 
topography of the association of bile acid profiles with glucose metabolism in an unbiased 
manner. For a voxel-based analysis of FDG-PET scans, we identified significant associations 
(cluster wise threshold of FDR-corrected p < 0.05). Higher GCDCA levels were 
significantly associated with reduced glucose metabolism especially in the bilateral 
hippocampi. Increased GLCA and GLCA:CDCA levels were significantly associated with 
reduced glucose metabolism in the bilateral temporal and parietal lobes. Lower TLCA levels 
were associated with increased glucose metabolism in the left temporal lobe. For two ratios 
(GDCA:CA and TDCA:CA), higher ratio levels were significantly associated with reduced 
glucose metabolism in a widespread pattern, especially in the bilateral frontal, parietal, and 
temporal lobes.
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Table 1.
Demographics of ADNI participants stratified by baseline diagnosisa.
Variable N CN (N=370) SMC (N=98) EMCI (N=284) LMCI (N=505) AD (N=305)
Age 1562 74.58(5.71) 72.18(5.63) 71.12(7.51) 73.95(7.59) 74.70(7.79)
Sex: Female, No. (%) 1562 190(51) 56(57) 130(46) 139(39) 139(46)
Education, years 1562 16.28(2.92) 16.71(2.56) 15.95(2.66) 15.87(2.90) 15.16(3.00)
BMI (Kg/M2) 1562 27.05(4.46) 28.22(6.24) 28.06(5.41) 26.54(4.25) 25.83(4.69)
APOE ε4 status, (+%) 1562 104(28) 32(33) 121(43) 273(54) 202(66)
CSF Aβ1–42 1112 1342.2(663.7) 1385.7(605.0) 1175.1(569.3) 896.5(502.7) 683.0(394.6)
CSF p-tau 1107 22.3(9.4) 21.7(9.6) 24.1(13.8) 30.5(14.8) 36.5(15.7)
CSF t-tau 1108 240.9(91.7) 237.9(92.7) 255.2(122.5) 309.7(130.3) 365.9(141.7)
a
Data are reported as mean(SD) unless otherwise indicated
Abbreviations: AD: Alzheimer’s disease; BMI: Body mass index; CN: Cognitively normal; EMCI: Early mild cognitive impairment; LMCI: Late 
mild cognitive impairment; SMC: subjective memory complaint; CSF: cerebrospinal fluid
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Table 2.
Levels of primary and secondary bile acids measured in the ADNI cohort stratified by clinical diagnosisa.
Bile Acid Category Nb CN (N=370) SMC (N=98) EMCI (N=284) LMCI (N=505) AD (N=305)
CA, Cholic Primary 1446 0.221(0.024) 0.245(0.093) 0.155(0.021) 0.192(0.021) 0.135(0.025)
CDCA, Chenodeoxycholic Primary 1357 0.285(0.042) 0.315(0.128) 0.241(0.034) 0.288(0.033) 0.216(0.033)
GCA, Glycocholic Primary Conjugated 1463 0.236(0.019) 0.269(0.046) 0.234(0.021) 0.239(0.014) 0.297(0.037)
GCDCA, Glycochenodeoxycholic Primary Conjugated 1464 0.658(0.035) 0.702(0.078) 0.724(0.059) 0.710(0.037) 0.806(0.049)
TCA, Taurocholic Primary Conjugated 1020 0.068(0.008) 0.090(0.029) 0.057(0.006) 0.068(0.006) 0.066(0.009)
TCDCA, Taurochenodeoxycholic Primary Conjugated 1426 0.090(0.006) 0.114(0.025) 0.088(0.007) 0.091(0.006) 0.097(0.008)
TMCA, Tauromuricholic Primary Conjugated 1146 0.012(0.001) 0.007(0.001) 0.011(0.001) 0.014(0.002) 0.014(0.002)
DCA, Deoxycholic Secondary 1445 0.526(0.041) 0.520(0.068) 0.574(0.043) 0.529(0.026) 0.627(0.045)
UDCA, Ursodeoxycholic Secondary 1111 0.065(0.007) 0.044(0.008) 0.072(0.011) 0.091(0.010) 0.087(0.012)
GDCA, Glycodeoxycholic Secondary Conjugated 1439 0.440(0.034) 0.462(0.063) 0.488(0.038) 0.502(0.031) 0.672(0.054)
TDCA, Taurodeoxycholic Secondary Conjugated 1430 0.058(0.006) 0.077(0.019) 0.059(0.005) 0.065(0.005) 0.077(0.006)
GLCA, Glycolithocholic Secondary Conjugated 1037 0.027(0.002) 0.025(0.003) 0.034(0.003) 0.030(0.002) 0.039(0.003)
TLCA, Taurolithocholic Secondary Conjugated 1008 0.005(0.0002) 0.004(0.001) 0.005(0.0003) 0.005(0.0003) 0.006(0.0005)
GUDCA, Glycoursodeoxycholic Secondary Conjugated 1401 0.115(0.010) 0.093(0.015) 0.114(0.012) 0.129(0.012) 0.136(0.015)
TUDCA, Tauroursodeoxycholic Secondary Conjugated 1369 0.008(0.001) 0.008(0.001) 0.008(0.001) 0.008(0.001) 0.008(0.001)
aValues represent μM in mean (standard error of the mean).
bNumber of non-missing measurements.
Abbreviations: AD: Alzheimer’s disease; CN: Cognitively normal; EMCI: Early mild cognitive impairment; LMCI: Late mild cognitive 
impairment; SMC: subjective memory complaint
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